{
  "id": 11136476,
  "title": "Enliven Therapeutics stock initiated at Overweight by JPMorgan",
  "url": "https://urgent.news/2026/10/01/enliven-therapeutics-stock-initiated-at-overweight-by-jpmorgan",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-01T07:32:47.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/enliven-therapeutics-stock-initiated-at-overweight-by-jpmorgan-93CH-4926443"
  },
  "original_language": "en",
  "account": "JPMorgan began tracking Enliven Therapeutics (NASDAQ:ELVN) with an \"Overweight\" rating and a price target of $75.00, indicating a 64% potential gain from the current price of $45.84. This aligns with the majority of analysts who maintain a \"Strong Buy\" rating and price targets between $64 and $82. The stock has skyrocketed nearly 198% year-to-date. However, InvestingPro's analysis questions whether the stock is overvalued when compared to its estimated fair value. The firm's focus is on ELVN-001, a unique ATP-competitive BCR::ABL inhibitor that offers a distinct option for treating chronic-phase CML. It targets patients who have progressed beyond the first-line treatment and aims to expand to frontline patients. While the allosteric approach of asciminib has enhanced tolerability and sidestepped many ATP-site resistance mutations, the emergence of myristoyl-pocket resistance demands an ATP-competitive TKI like ELVN-001. This gives doctors a choice of switching drug classes for subsequent therapy while maintaining a high safety profile. Enliven Therapeutics is in a strong position to become the preferred treatment for post-asciminib patients and frontline patients due to its extensive mutational coverage and persistent activity against mutations linked to asciminib. The company is currently holding more cash than debt on its balance sheet, providing it with the financial flexibility to fund its clinical development programs. Analysts predict U.S. peak sales of around $5 billion or more across chronic-phase CML, evenly split between frontline and 2L+ chronic-phase CML. The critical turning point is the transition from phase 1 ENABLE data at the selected 80mg once-daily Phase 3 dose into the planned randomized ENABLE-2 pivotal program. Recently, other firms have also taken interest in Enliven Therapeutics. William Blair started tracking the company with an \"Outperform\" rating, emphasizing the expanding CML market and the need for better treatment options. Barclays also began tracking with an \"Overweight\" rating and set a price target of $78. Guggenheim lowered its price target slightly to $78 from $80 but kept a \"Buy\" rating following the company's Q2 2026 results and an update on ELVN-001's development. H.C. Wainwright raised its price target for Enliven Therapeutics to $65 from $56, keeping a \"Buy\" rating, based on improved chances for ELVN-001's approval, spurred by new data from the Phase 1 ENABLE trial. These recent moves show a rising interest in Enliven Therapeutics from the investment community, primarily around its lead asset, ELVN-001.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "JPMorgan initiates Kura Oncology stock with overweight rating",
        "url": "https://urgent.news/2026/10/01/jpmorgan-initiates-kura-oncology-stock-with-overweight-rating",
        "published": "2026-10-01T07:32:53.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}